All In Biotech

Drug Trial Radar · NCT00280566

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment With Both Agents

Last checked: Nov 20, 2026Latest source record: Mar 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 584 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

584

Actual

Start

Dec 2005

Primary completion

May 2008

Study completion May 2008

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the regimen.

Conditions

  • Bipolar Mania
  • Bipolar Disorder

Interventions

  • PlaceboDrug

    Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.

  • Ziprasidone Oral CapsuleDrug

    Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Intervention for a Mood Episode During Double Blind PeriodTime frame: Period 2: 24 weeks or time of early termination

Locations

107 sites in 13 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Scottsdale, Arizona

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Costa Mesa, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    National City, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Temecula, California

  • Pfizer Investigational Site

    Temecula, California

  • Pfizer Investigational Site

    Altamonte Springs, Florida

  • Pfizer Investigational Site

    Fort Lauderdale, Florida

  • Pfizer Investigational Site

    Fort Myers, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Maitland, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    North Miami, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Tavares, Florida

  • Pfizer Investigational Site

    Decatur, Georgia

  • Pfizer Investigational Site

    Smyrna, Georgia

  • Pfizer Investigational Site

    Honolulu, Hawaii

  • Pfizer Investigational Site

    Des Plaines, Illinois

  • Pfizer Investigational Site

    Libertyville, Illinois

  • Pfizer Investigational Site

    Naperville, Illinois

  • Pfizer Investigational Site

    Naperville, Illinois

  • Pfizer Investigational Site

    Oak Brook, Illinois

  • Pfizer Investigational Site

    Schaumburg, Illinois

  • Pfizer Investigational Site

    Terre Haute, Indiana

  • Pfizer Investigational Site

    Topeka, Kansas

  • Pfizer Investigational Site

    Wichita, Kansas

  • Pfizer Investigational Site

    Lexington, Kentucky

  • Pfizer Investigational Site

    Owensboro, Kentucky

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Rockville, Maryland

  • Pfizer Investigational Site

    Pittsfield, Massachusetts

  • Pfizer Investigational Site

    Taunton, Massachusetts

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.